Century Therapeutics (IPSC) Competitors

Opthea (NASDAQ:OPT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Is OPT or IPSC more profitable?

Opthea has a net margin of 0.00% compared to Century Therapeutics' net margin of -2,127.33%. Opthea's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opthea	N/A	N/A	N/A
Century Therapeutics	-2,127.33%	-39.33%	-25.10%

Do analysts rate OPT or IPSC?

Opthea currently has a consensus target price of $22.50, suggesting a potential upside of 614.29%. Century Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 468.86%. Given Opthea's higher possible upside, equities analysts plainly believe Opthea is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opthea	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of OPT or IPSC?

13.9% of Opthea shares are held by institutional investors. Comparatively, 35.8% of Century Therapeutics shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 7.6% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor OPT or IPSC?

In the previous week, Opthea's average media sentiment score of 0.00 equaled Century Therapeutics' average media sentiment score.

Company	Overall Sentiment
Opthea	Neutral
Century Therapeutics	Neutral

Which has preferable valuation and earnings, OPT or IPSC?

Opthea has higher earnings, but lower revenue than Century Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opthea	$90 thousand	2,044.00	-$92.82 million	N/A	N/A
Century Therapeutics	$5.20 million	38.27	-$130.93 million	-$2.15	-1.55

Which has more risk & volatility, OPT or IPSC?

Opthea has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Does the MarketBeat Community believe in OPT or IPSC?

Century Therapeutics received 8 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 59.46% of users gave Century Therapeutics an outperform vote while only 51.85% of users gave Opthea an outperform vote.

Company	Underperform	Outperform
Opthea	Outperform Votes 14 51.85%	Underperform Votes 13 48.15%
Century Therapeutics	Outperform Votes 22 59.46%	Underperform Votes 15 40.54%

Summary

Century Therapeutics beats Opthea on 7 of the 13 factors compared between the two stocks.